Loading
Everything OnCo dates to 2024: 733 entries, 142 landmarks, 132 papers, 113 trials reported and 96 regulatory events. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
733 dated entries in OnCo fall in 2024: 142 landmarks, 132 papers, 113 trials reported, 96 regulatory events, 91 papers listed on people's pages, 84 approvals, 31 financing rounds, 29 technologies, 10 guideline changes, 3 expected dates and 2 laws and regulations.
Of those, 77 to the day, 30 to the month and 626 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional). Conditional marketing authorisation
KRAS G12C colorectal cancer with cetuximab
KRAS G12C-mutated locally advanced or metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with cetuximab.
Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)
Adjuvant ALK+ NSCLC after resection (stage IB ≥4 cm to IIIA)
First-line EGFR-mutant NSCLC with lazertinib
Newly diagnosed Ph+ CML in chronic phase (ASC4FIRST)
Extensive-stage small-cell lung cancer, first line, with anlotinib and platinum-etoposide chemotherapy
Consolidation in CD19+ B-ALL regardless of MRD
First-line persistent/recurrent/metastatic cervical cancer with chemotherapy ± bevacizumab; first-line gastric cancer with chemotherapy
ER+/HER2- mBC with PIK3CA/AKT1/PTEN alteration; 17 Jun 2024
KRAS G12C mCRC with adagrasib
Relapsed myeloma after ≥1 line, lenalidomide-refractory
Colorectal cancer screening in average-risk adults aged 45 and older
Metastatic or locally advanced cutaneous SCC not curable by surgery or radiation
ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor.
Newly diagnosed transplant-eligible with VRd (PERSEUS)
Relapsed or refractory stage I to III CTCL after at least one systemic therapy (Lymphir)
Primary advanced/recurrent endometrial cancer with chemotherapy (all-comers)
Locally advanced, unresectable or metastatic biliary tract cancer with gemcitabine and cisplatin; NICE TA944 recommended 10 January 2024 with a commercial arrangement.
Reduction in duration of neutropenia and febrile neutropenia after cytotoxic chemotherapy in adults (excluding CML and MDS)
Metastatic colorectal cancer with a BRAF V600E mutation, with cetuximab and mFOLFOX6, previously untreated. Accelerated approval on 20 December 2024 on BREAKWATER.
ALK-positive locally advanced or metastatic NSCLC, ALK-inhibitor-naive
Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)
FGFR3-altered advanced urothelial cancer after ≥1 systemic therapy incl. PD-1/PD-L1 (full)
Previously treated metastatic colorectal cancer. Fruzaqla marketing authorisation issued 20 June 2024.
KRAS G12C-mutant advanced NSCLC after at least one systemic therapy
Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one systemic treatment; NICE TA1005 recommended 11 September 2024 as an alternat...
KRAS G12C-mutant advanced NSCLC after at least one systemic therapy
KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy
Relapsed or refractory peripheral T-cell lymphoma
After ≥2 lines including IMiD, PI, and anti-CD38
Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure
PIK3CA-mutant HR+/HER2- advanced breast cancer with palbociclib and fulvestrant
Paediatric patients ≥1 year with relapsed/refractory CD22+ B-ALL
Recurrent or metastatic cervical cancer after platinum chemotherapy
Liposomal irinotecan in NALIRIFOX first-line metastatic pancreatic cancer
Newly diagnosed transplant-ineligible with VRd (IMROZ)
EGFR-mutant NSCLC after TKI (with chemotherapy); first-line PD-L1+ NSCLC
Locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after one or more systemic treatments; NICE TA948 recommended 31 January 2024 with a commercial arrange...
First-line EGFR exon 19 del / L858R NSCLC with amivantamab
Unresectable/metastatic melanoma after anti-PD-1 (and BRAF/MEK if applicable)
Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy
First-line metastatic pancreatic adenocarcinoma in NALIRIFOX (NAPOLI 3). FDA label (DailyMed)
Relapsed/refractory CLL/SLL after BTK inhibitor and BCL-2 inhibitor (accelerated)
Paediatric ≥12 years; first-line (NETTER-2 label)
WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over
Companion diagnostic claims across several solid tumours, with tumour-profiling claims
FRα+ platinum-resistant ovarian; 14 Nov 2024
Myelofibrosis with moderate-to-severe anaemia
First-line metastatic pancreatic adenocarcinoma
BCG-unresponsive NMIBC with CIS ± papillary tumours, with BCG
Relapsed or refractory B-cell precursor ALL, adults
R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)
Metastatic NSCLC after platinum with PD-1 or docetaxel
Fluorescence imaging in adults with breast cancer as an adjunct for intraoperative detection of residual cancer after lumpectomy
Resectable non-small-cell lung cancer at high risk of recurrence, neoadjuvant with platinum chemotherapy then adjuvant alone.
Newly diagnosed Ph+ ALL with chemotherapy (accelerated)
Steroid-refractory acute graft-versus-host disease in children aged two months and older
NTRK-fusion solid tumours (tumour-agnostic)
Merkel cell carcinoma
Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1
Adjuvant stage II-III HR+/HER2- breast cancer at high risk of recurrence
Pretreated advanced TNBC; later EGFR-mutant NSCLC after TKI
Colorectal cancer screening, average-risk adults ≥45
First-line metastatic NSCLC with platinum chemotherapy, no sensitising EGFR, ALK, ROS1 or RET alterations
HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations after an anthracycline or a taxane; NICE TA952 (21 February 2024) recommends withi...
Extensive-stage SCLC after platinum chemotherapy
Second-line ESCC after chemotherapy; first-line HER2-negative gastric/GEJ with chemotherapy (PD-L1 ≥1)
Relapsed/refractory BRAF-altered paediatric low-grade glioma (accelerated)
HER2-low metastatic or unresectable breast cancer after chemotherapy: NICE TA992 (29 July 2024) does not recommend trastuzumab deruxtecan, the cost per quality-adjusted life year b...
HER2 IHC3+ solid tumours (tumour-agnostic)
Unresectable or metastatic HER2-positive (IHC 3+) solid tumours after previous systemic treatment, including colorectal cancer.
Metastatic colorectal cancer after two lines of treatment, with bevacizumab. TA1008, published 25 September 2024, recommends the combination within its marketing authorisation subj...
Companion diagnostic for larotrectinib (NTRK fusions) with tumour-profiling claims
Advanced NRAS-mutant melanoma after prior immunotherapy
Relapsed or refractory B-cell lymphoma. CDSCO market authorisation as announced by Immuneel; ARI-0001 is separately approved in Spain under the hospital exemption
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
HER2+ (IHC 3+) unresectable/metastatic biliary tract cancer, previously treated. Ziihera label (openFDA); 53% of HERIZON-BTC-01 patients had gallbladder cancer: https://api.fda.gov...
NRG1-fusion NSCLC and pancreatic adenocarcinoma
Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent
1L CLDN18.2+ HER2- gastric/GEJ; 19 Sep 2024
CLDN18.2+ HER2- gastric cancer (first approval, March 2024)
First-line CLDN18.2+ (≥75%), HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with fluoropyrimidine/platinum chemotherapy
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Phase 3 PRISM-MEL-301 initiated after FDA alignment on design
Breakthrough Therapy designation for HNSCC
Class boxed warning for T-cell malignancies
Class boxed warning for T-cell malignancies
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has: susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or follo...
Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Fast Track designation
Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK...
First-line with chemotherapy (FLAURA2)
Biweekly dosing added for responders
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy...
BMS completes RayzeBio acquisition ($4.1B)
Second-line ESCC (RATIONALE-302)
World-first approval
Breakthrough Therapy designation
Treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as dete...
Paediatric expansion
Adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.
First CAR-T in CLL (TRANSCEND CLL 004), accelerated
Treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
Adult patients with relapsed/ refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least two prior lines of therapy in...
Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior...
CRLs for DLBCL and FL, confirmatory trial enrolment status
Relapsed myeloma after ≥1 prior line, lenalidomide-refractory (CARTITUDE-4)
Adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options...
Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved t...
Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who requ...
Formulation: Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no sat...
Class boxed warning for T-cell malignancies
Paediatric patients ≥12 years
Patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
Formulation: Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy...
Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Full approval with OS benefit (innovaTV 301)
First CRL: manufacturing inspection findings
Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)
Adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.
Treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or...
Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
FDA advisory committee votes favourably
EGFR-mutant NSCLC after TKI, with chemotherapy (HARMONi-A)
Paediatric ≥2 years
AstraZeneca completes Fusion Pharmaceuticals acquisition; FPI-2265 phase 3 planned
Breakthrough Therapy designation, previously treated metastatic PDAC
Breakthrough Therapy for MRCLS
First-line label based on NETTER-2
Breakthrough Therapy designation, ROS1+ NSCLC after prior ROS1 TKI
In combination with cetuximab for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluo...
Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-re...
Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who requ...
Treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or...
Consolidation in CD19+ Ph-negative B-ALL regardless of MRD (E1910)
KRAS G12C colorectal cancer with cetuximab (accelerated)
Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Complete response letter citing third-party manufacturing inspection
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose...
PMA approval: first blood test for primary colorectal cancer screening (ECLIPSE)
Dara-VRd induction/consolidation (PERSEUS)
Breakthrough Therapy designation, extensive-stage SCLC after platinum
Conditional approval DLBCL and FL
Medicare coverage under the blood-based CRC screening NCD
Accelerated approval, MAGE-A4+ HLA-A*02+ advanced synovial sarcoma (SPEARHEAD-1): first TCR-T for a solid tumour
All-comer primary advanced/recurrent endometrial cancer with chemotherapy
Treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose t...
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma
First-line EGFR-mutant NSCLC with lazertinib (MARIPOSA)
First-line cervical cancer (COMPASSION-16)
Subcutaneous atezolizumab (Tecentriq Hybreza)
Adjuvant stage II-III HR+/HER2- early breast cancer at high risk (NATALEE)
After osimertinib, with chemotherapy (MARIPOSA-2)
IMROZ frontline
Unresectable stage III after chemoradiation (LAURA)
Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy *.
Formulation: Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved t...
Merck co-development of R-DXd under the Daiichi Sankyo alliance
PIK3CA-mutant HR+/HER2- endocrine-resistant advanced breast cancer with palbociclib and fulvestrant (INAVO120)
Optune Lua, metastatic NSCLC after platinum (LUNAR)
SPOTLIGHT/GLOW; companion diagnostic VENTANA CLDN18 (43-14A)
Treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
EMA approval
Urothelial cancer indication voluntarily withdrawn after TROPiCS-04
NMPA approval, pretreated advanced TNBC (OptiTROP-Breast01); first TROP2 ADC approved in China
FELIX; approved without REMS
Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1: first menin inhibitor
Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
Treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death...
First-line gastric/GEJ (RATIONALE-305)
Breakthrough Therapy designation, EGFR-mutant NSCLC after TKI
Limited-stage SCLC after chemoradiation (ADRIATIC)
Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior system...
Treatment of adults with advanced unresectable or metastatic nonsmall cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prio...
Approved for cSCC
In combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Formulation: As monotherapy or as monotherapy following treatment with intravenous nivolumab and ipilimumab combination therapy for the treatment of adult patients with microsatell...
Formulation: Treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib and following treatment with intravenous nivolumab and...
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, statute.
United States, regulation.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
2 rows added. Anchored to Annals of Oncology publication, 2024.
1 row added. Anchored to FDA accelerated approval of lisocabtagene maraleucel for CLL after BTK and BCL-2 inhibitors, March 2024 (TRANSCEND CLL 004).
1 row recategorised, 1 row added. Anchored to FDA approvals of enfortumab vedotin with pembrolizumab (December 2023, EV-302) and nivolumab with gemcitabine-cisplatin (March 2024, C...
2 rows added. Anchored to FDA accelerated approval of lifileucel (February 2024) and NADINA publication (NEJM, June 2024).
1 row recategorised. Anchored to FDA approvals of dostarlimab with carboplatin-paclitaxel for dMMR disease (July 2023, RUBY), pembrolizumab with carboplatin-paclitaxel (June 2024...
1 row recategorised, 2 rows added. Anchored to FDA approvals of cilta-cel in the second line and ide-cel in the third line (April 2024, CARTITUDE-4 and KarMMa-3), D-VRd (July 2024...
3 rows added. Anchored to FDA approvals of osimertinib with chemotherapy (February 2024, FLAURA2), adjuvant alectinib (April 2024, ALINA), amivantamab with lazertinib (August 2024...
2 rows added. Anchored to FDA approvals of pembrolizumab with chemotherapy for HER2-negative disease (November 2023, KEYNOTE-859) and zolbetuximab (October 2024, SPOTLIGHT and GLOW...
2 rows added. Anchored to FDA approval of pembrolizumab with chemoradiation for FIGO 2014 stage III-IVA disease (January 2024, KEYNOTE-A18); INTERLACE publication (Lancet, October...
2 rows added. Anchored to FDA approvals of adjuvant ribociclib (September 2024, NATALEE) and inavolisib (October 2024, INAVO120).
The year reported on trial records, with the headline result the record gives.
Registry record NCT05243550; no result is recorded here.
Registry record NCT05246514; no result is recorded here.
Registry record NCT04606771; no result is recorded here.
Registry record NCT04489771; no result is recorded here.
Registry record NCT04538664; no result is recorded here.
Registry record NCT04023526; no result is recorded here.
Eighteen-month event-free survival 70.2 percent with perioperative nivolumab against 50.0 percent with chemotherapy alone (hazard ratio 0.58, 97.36 percent confidence interval 0.42...
Registry record NCT04172597; no result is recorded here.
Repotrectinib produced responses in 79 percent of ROS1 inhibitor-naive patients (median progression-free survival 35.7 months) and 38 percent after one ROS1 inhibitor, including 59...
Registry record NCT03673501; no result is recorded here.
Registry record NCT04639219; no result is recorded here.
Registry record NCT04721977; no result is recorded here.
In the follicular lymphoma cohort, objective response 80.0 per cent and complete response 73.4 per cent, with median duration of complete response 25.1 months and median progressio...
Primary DFS endpoint not met (figures not indexed); exploratory: avelumab benefit only with baseline TILs 30% or more (stratum B 3-year DDFS 92.0% vs 58.7%, HR 0.20; interaction p...
Registry record NCT02788981; no result is recorded here.
PFS 11.3 vs 8.2 months, HR 0.64.
OS 55.9 vs 33.4 months, HR 0.73.
3-year PFS 76.5% (AV) / 83.1% (AVO) vs 66.5%.
Subcutaneous daratumumab delayed progression to active myeloma or death compared with active monitoring in high-risk smouldering myeloma; approved in the United States in 2025.
Darolutamide plus androgen deprivation lengthened radiographic progression-free survival compared with androgen deprivation alone; approved for this use in 2025.
CR+CRh 22.8%, ORR 63.2% in KMT2Ar cohort.
No overall survival benefit from adding devimistat to modified FOLFIRINOX.
Registry record NCT04579380; no result is recorded here.
OS not significantly improved overall; benefit in non-epithelioid subgroup.
Sensitivity 93.9% for colorectal cancer (FIT 67.3%); specificity 90.6% for advanced neoplasia.
CR 75.2%; 24-month CR 41.8%.
PFS 11.2 vs 8.7 months; HR 0.58.
PFS HR 0.23 (pNET), 0.38 (epNET).
No kidney rejection or graft loss in 12 kidney transplant recipients given cemiplimab after cross-taper to a mammalian target of rapamycin inhibitor with pulsed corticosteroids, wi...
MRD-neg 60.9% vs 39.4%; PFS HR 0.57.
First-line PFS 54.1 vs 5.9 months (HR 0.21); combination vs nivolumab PFS HR 0.62.
OS 23.7 vs 20.6 months, HR 0.79; ORR 36% vs 13%.
Ibrutinib delayed progression to symptomatic disease but did not improve survival: five-year overall survival 93.3 percent against 93.6 percent with placebo; watch and wait remains...
3-year DFS 96.0% vs 87.9%; HR 0.39.
Registry record NCT02883049; no result is recorded here.
At two years the rate of ipsilateral invasive cancer with active monitoring was non-inferior to guideline-concordant surgery.
OS HR 0.64; PFS HR 0.62.
Three-year event-free survival 86 percent with sintilimab added to chemoradiotherapy against 76 percent without (hazard ratio 0.59, p 0.019); grade 3 to 4 adverse events 74 against...
Median overall survival 16.1 months with MRI-guided stereotactic ablative radiotherapy against 12.5 months with irreversible electroporation (hazard ratio 1.39, 95 percent confiden...
Median progression-free survival 6.1 months with molecularly guided therapy versus 4.4 months with continued chemotherapy (hazard ratio 0.72); overall survival immature.
PFS HR 0.62.
CNS ORR 71.7%; 12-month PFS 61.6% in brain-metastasis cohort.
PFS 36.6 vs 13.4 months, HR 0.41; OS HR 0.58.
PFS HR 0.52.
Registry record NCT03837899; no result is recorded here.
Sensitivity 83.1% for colorectal cancer, 13.2% for advanced precancerous lesions; specificity 89.6%.
3-year OS 85% vs 68%; HR 0.41.
PFS HR 0.62 (ESR1-mutant, monotherapy); HR 0.57 (combination vs monotherapy).
PFS HR 0.77; OS HR 0.80, not significant.
Perioperative FLOT improved overall survival compared with CROSS chemoradiotherapy in resectable oesophageal adenocarcinoma.
ORR 77%, CR 55%; grade ≥3 CRS 2.4%.
Progression-free survival at 12 months 36 percent with sunitinib against 19 percent with placebo, meeting the primary endpoint of the first randomised trial in the disease.
Objective response rate 36.3% by independent central review in 91 treated patients (complete response 7.7%), above the prespecified historical benchmark; median duration of respons...
ORR about 96% in infused patients (JAMA Oncol 2024).
Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.
4-year PFS 94.3% vs 90.9%, HR 0.66; less toxicity.
PFS HR 0.51; OS statistically significant (2026 announcement).
PFS 7.1 vs 4.8 months, HR 0.46.
Registry record NCT04619004; no result is recorded here.
Ongoing; the first block results and de-escalation rates were reported from 2024.
30-month progression-free survival 96.7% (observation) vs 98.5% (radiotherapy) in patients with complete metabolic response; radiotherapy can be omitted.
ORR 42%.
PFS HR 0.60.
Brigatinib produced radiographic responses in 10 percent of target tumours and 23 percent of all tumours, slowed growth of every tumour type and improved hearing in 35 percent of e...
PFS 7.4 vs 6.1 months (HR 1.02, 0.71 to 1.45); OS 24.4 vs 24.9 months (HR 1.08). Negative.
PFS HR 0.58.
Primary overall survival endpoint not met.
PFS HR 0.16.
PFS HR 0.66; final OS HR 0.98.
Registry record NCT02159066; no result is recorded here.
ORR 70%, ≥CR 45%.
ORR 28.6% overall; 34.6% in c-Met high, 22.9% in c-Met intermediate.
Registry record NCT03975907; no result is recorded here.
Registry record NCT04313881; no result is recorded here.
Pelabresib plus ruxolitinib roughly doubled the week-24 spleen volume response over ruxolitinib alone; the symptom endpoint did not reach significance.
OS HR 1.28 favouring no surgery; median 19.3 vs 24.8 months.
Registry record NCT04642469; no result is recorded here.
Relapse-free survival hazard ratio 0.679 for gilteritinib against placebo, not statistically significant overall; in the prespecified MRD-positive half of patients the hazard ratio...
ORR 40% vs 0%.
12-month EFS 83.7% vs 57.2%; HR 0.32.
OS 6.9 vs 8.2 months; not improved.
pCR 58% (48 to 67); RCB 0 or 1 69%; 3-year EFS 86% (98% with pCR, 68% without).
Median event-free survival not estimable against 15.1 months in stage III disease (hazard ratio 0.40, 95 percent confidence interval 0.28 to 0.57).
EFS HR 0.68; OS HR 0.75.
Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.032); median overall survival 25.1 against 38.5 months (hazard ratio 1.52, p...
5-year biochemical or clinical failure-free 95.8% (SBRT) vs 94.6% (conventional), non-inferior.
Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.
No difference between protons and IMRT in EPIC bowel quality of life at 24 months (primary endpoint, p=0.836) or in urinary or sexual function; five-year progression-free survival...
Germline BRCA group: three-year survival 100 percent (39 patients, one relapse) with the gap schedule versus 88 percent (45 patients, nine relapses) with chemotherapy alone (Univer...
Palbociclib added to maintenance anti-HER2 and endocrine therapy lengthened progression-free survival.
Registry record NCT03126630; no result is recorded here.
MRD-negative CR 34.4% vs 16.7%.
3-year iDFS 95.4% in the PET-adapted arm; ~1 in 3 spared chemotherapy.
Placebo-adjusted weight gain 2.81 kg at 400 mg over 12 weeks; improved appetite and activity.
PFS 6.0 vs 5.3 months, HR 0.73.
Ten-year metastasis-free survival 78.1 percent with 24 months of androgen deprivation against 71.9 percent with 6 months (hazard ratio 0.773, 95 percent confidence interval 0.612 t...
ORR 44%, median PFS 19.6 months in KRAS-mutant LGSOC.
Registry record NCT04154956; no result is recorded here.
Five-year recurrence-free survival 89.7 percent with sentinel node biopsy alone against 88.7 percent with completion axillary clearance (hazard ratio 0.89, 0.66 to 1.19, non-inferi...
Simple hysterectomy was non-inferior to radical hysterectomy for three-year pelvic recurrence in low-risk early cervical cancer, with fewer urinary complications.
rPFS HR 0.71; interim OS HR 1.11.
Overall survival hazard ratio 0.62. A US advisory committee voted 8 to 1 that the trial was not applicable to the US population, and the second-line indication is absent from the U...
Registry record NCT04956692; no result is recorded here.
Registry record NCT03801525; no result is recorded here.
Registry record NCT04711135; no result is recorded here.
Registry record NCT03972488; no result is recorded here.
CR 82%; 51% in CR at 12 months.
Registry record NCT04205630; no result is recorded here.
PFS HR 1.10; no benefit from nivolumab rechallenge.
Registry record NCT02762266; no result is recorded here.
Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0...
EFS 19.4 vs 33.1 months (worse with xevinapant).
Registry record NCT04703192; no result is recorded here.
The publication year on key paper records.
Shuch B, Pantuck AJ, Bernhard JC, et al. The Lancet Oncology.
Morris MJ, Castellano D, Herrmann K, et al. The Lancet.
Pérez-García JM, Cortés J, Ruiz-Borrego M, et al. The Lancet.
Chung DC, Gray DM, Singh H, et al. New England Journal of Medicine.
Vorontsov E, Bozkurt A, Casson A, et al. Nature Medicine.
Wang X, Zhao J, Marostica E, et al. Nature.
Tang XX, Shimada H, Ikegaki N. Current oncology.
Lu MY, Chen B, Williamson DFK, et al. Nature Medicine.
Xu H, Usuyama N, Bagga J, et al. Nature.
Abramson J, Adler J, Dunger J, et al. Nature.
Loibl S, Jassem J, Sonnenblick A, et al. Journal of Clinical Oncology.
Cheng Y, Spigel DR, Cho BC, et al. New England Journal of Medicine.
Wu YL, Dziadziuszko R, Ahn JS, et al. New England Journal of Medicine.
Besse B, Pons-Tostivint E, Park K, et al. Nature Medicine.
Bullock AJ, Schlechter BL, Fakih MG, et al. Nature Medicine.
Bray F, Laversanne M, Sung H, et al. CA: A Cancer Journal for Clinicians.
Oliveira M, Pominchuk D, Nowecki Z, et al. The Lancet Oncology.
Han B, Zheng R, Zeng H, et al. Journal of the National Cancer Center.
Braun IM, Bohlke K, Abrams DI, et al. Journal of Clinical Oncology.
Shirley M. Drugs.
Wolf J, Hochmair M, Han JY, et al. The Lancet Oncology.
Mondaca S, Walch H, Sepulveda S, et al. JCO Global Oncology.
Segal NH, Tie J, Kopetz S, et al. British Journal of Cancer.
Perez JK, Kleber J, Rothe M, et al. JCO Precision Oncology.
Holderfield M, Lee BJ, Jiang J, et al. Nature.
Liu X, Zhang Y, Yang KY, et al. The Lancet.
Krämer A, Bochtler T, Pauli C, et al. The Lancet.
Bardia A, Hu X, Dent R, et al. New England Journal of Medicine.
Meric-Bernstam F, Makker V, Oaknin A, et al. Journal of Clinical Oncology.
Philip PA, Sahai V, Bahary N, et al. Journal of Clinical Oncology.
Westin SN, Moore K, Chon HS, et al. Journal of Clinical Oncology.
Wirth LJ, Brose MS, Subbiah V, et al. Journal of Clinical Oncology.
Oh DY, He AR, Bouattour M, et al. The lancet. Gastroenterology & hepatology.
Loibl S, André F, Bachelot T, et al. Annals of Oncology.
Litzow MR, Sun Z, Mattison RJ, et al. New England Journal of Medicine.
Zhou Q, Meng X, Sun L, et al. Journal of Thoracic Oncology.
Li W, Xiong A, Yang N, et al. Journal of Clinical Oncology.
Zager JS, Orloff M, Ferrucci PF, et al. Annals of surgical oncology.
Li C, Zhou K, Hu Y, et al. JAMA Oncology.
Powles T, Valderrama BP, Gupta S, et al. New England Journal of Medicine.
Ghai A, Sabour E, Salonga R, Ho R, Apollonio DE. Public Health Reports.
Natrajan K, Kaushal M, George B, et al. Clinical Cancer Research.
Dierks A, Gäble A, Rinscheid A, et al. Journal of Nuclear Medicine.
Dudnichenko O, Penkov K, McKean M, et al. European Journal of Cancer.
Wang ZX, Peng J, Liang X, et al. Med (New York, N.Y.).
Baudin E, Goichot B, Berruti A, et al. The Lancet.
Kraljevic Z, Bean D, Shek A, et al. The Lancet Digital Health.
Cid V, Vargas C, Delgado I, et al. American Journal of Epidemiology.
Samaniego CP, de Aretxabala X, Castillo F, et al. Revista Medica de Chile.
Bedrosian I, Somerfield MR, Achatz MI, et al. Journal of Clinical Oncology.
Borchmann P, Ferdinandus J, Schneider G, et al. The Lancet.
Martín M, Lim E, Chavez-MacGregor M, et al. Journal of Clinical Oncology.
Abramson JS, Ku M, Hertzberg M, et al. The Lancet.
Martelli M, Ceriani L, Ciccone G, et al. Journal of Clinical Oncology.
Platzbecker U, Santini V, Fenaux P, et al. The Lancet.
Turner NC, Im SA, Saura C, et al. New England Journal of Medicine.
Mukohara T, Park YH, Sommerhalder D, et al. Nature Medicine.
Hansen AR, Probst S, Beauregard JM, et al. Frontiers in oncology.
Vergote I, González-Martín A, Fujiwara K, et al. New England Journal of Medicine.
McCormack M, Eminowicz G, Gallardo D, et al. The Lancet.
Stier EA, Clarke MA, Deshmukh AA, et al. International Journal of Cancer.
Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. Pancreatology.
Plotkin SR, Yohay KH, Nghiemphu PL, et al. New England Journal of Medicine.
HARMONi-A Study Investigators, Fang W, Zhao Y, et al. JAMA.
Weber JS, Carlino MS, Khattak A, et al. The Lancet.
Lorusso D, Xiang Y, Hasegawa K, et al. The Lancet.
Lorusso D, Xiang Y, Hasegawa K, et al. The Lancet.
Montoya S, Bourcier J, Noviski M, et al. Science.
Hao M, Gong J, Zeng X, et al. Nature methods.
Brown CE, Hibbard JC, Alizadeh D, et al. Nature Medicine.
Walls GM, Mistry H, Barlesi F, et al. International Journal of Radiation Oncology, Biology, Physics.
Verheij FS, Omer DM, Williams H, et al. Journal of Clinical Oncology.
Kozono D, Hua X, Wu MC, et al. Journal of Thoracic Oncology.
Pant S, Wainberg ZA, Weekes CD, et al. Nature Medicine.
Cho BC, Lu S, Felip E, et al. New England Journal of Medicine.
Lim E, Waller D, Lau K, et al. The Lancet Respiratory Medicine.
Levis MJ, Hamadani M, Logan B, et al. Journal of Clinical Oncology.
Garralda E, Beaulieu ME, Moreno V, et al. Nature Medicine.
Blank CU, Lucas MW, Scolyer RA, et al. New England Journal of Medicine.
Vogel A, Saborowski A, Wenzel P, et al. The lancet. Gastroenterology & hepatology.
Slamon D, Lipatov O, Nowecki Z, et al. New England Journal of Medicine.
Singh S, Halperin D, Myrehaug S, et al. The Lancet.
Imperiale TF, Porter K, Zella J, et al. New England Journal of Medicine.
Powles T, Catto JWF, Galsky MD, et al. New England Journal of Medicine.
Chalabi M, Verschoor YL, Tan PB, et al. New England Journal of Medicine.
André T, Elez E, Van Cutsem E, et al. New England Journal of Medicine.
Labori KJ, Bratlie SO, Andersson B, et al. The Lancet Gastroenterology and Hepatology.
Arrillaga-Romany I, Gardner SL, Odia Y, et al. Journal of Clinical Oncology.
Lu S, Kato T, Dong X, et al. New England Journal of Medicine.
Hofman MS, Emmett L, Sandhu S, et al. The Lancet Oncology.
Schmid P, Cortes J, Dent R, et al. New England Journal of Medicine.
Sanders JJ, Temin S, Ghoshal A, et al. Journal of Clinical Oncology.
Efstathiou JA, Yeap BY, Michalski JM, et al. International Journal of Radiation Oncology, Biology, Physics.
Cascone T, Awad MM, Spicer JD, et al. New England Journal of Medicine.
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. New England Journal of Medicine.
van As N, Griffin C, Tree A, et al. New England Journal of Medicine.
Abou-Alfa GK, Galle PR, Chao Y, et al. Liver Cancer.
Groarke JD, Crawford J, Collins SM, et al. New England Journal of Medicine.
Roohani Y, Huang K, Leskovec J. Nature Biotechnology.
Naito Y, Nakamura S, Kawaguchi-Sakita N, et al. International journal of clinical oncology.
Martin RM, Turner EL, Young GJ, et al. JAMA.
Zeidan AM, Ando K, Rauzy O, et al. The Lancet Haematology.
Kim TM, Taszner M, Novelli S, et al. Annals of Oncology.
Cui H, Wang C, Maan H, et al. Nature methods.
Ma J, He Y, Li F, et al. Nature Communications.
Thakurdesai A, Rivera-Matos L, Nagra N, Busch B, Mais DD, Cave MC. ACG Case Reports Journal.
Plante M, Kwon JS, Ferguson S, et al. New England Journal of Medicine.
Siegel RL, Giaquinto AN, Jemal A. CA: A Cancer Journal for Clinicians.
D'Angelo SP, Araujo DM, Abdul Razak AR, et al. The Lancet.
Wang M, Fan Y, Sun M, et al. The Lancet. Respiratory medicine.
Herrera AF, LeBlanc M, Castellino SM, et al. New England Journal of Medicine.
Fizazi K, Bernard-Tessier A, Roubaud G, et al. NEJM Evidence.
Greer JA, Temel JS, El-Jawahri A, et al. JAMA.
Camidge DR, Bar J, Horinouchi H, et al. Journal of Clinical Oncology.
Martínez-Cibrián N, Ortiz-Maldonado V, Español-Rego M, et al. British journal of haematology.
Forcic D, Mrsic K, Peric-Balja M, Kurtovic T, Ramic S, Silovski T, Pedisic I, Milas I, Halassy B. Vaccines.
Kilburn LB, Khuong-Quang DA, Hansford JR, et al. Nature Medicine.
Slater S, Bryant A, Aresu M, et al. Clinical Cancer Research.
Chen RJ, Ding T, Lu MY, et al. Nature Medicine.
Zhu M, Madia P, Crawford A, et al. Clinical and translational science.
Harbeck N, Ciruelos E, Jerusalem G, et al. Nature Medicine.
Ohba A, Morizane C, Kawamoto Y, et al. Journal of Clinical Oncology.
Raghav K, Siena S, Takashima A, et al. The Lancet Oncology.
Li BT, Meric-Bernstam F, Bardia A, et al. The Lancet Oncology.
Dreyling M, Doorduijn J, Giné E, et al. The Lancet.
Drilon A, Camidge DR, Lin JJ, et al. New England Journal of Medicine.
Bardia A, Jhaveri K, Im SA, et al. Journal of Clinical Oncology.
Leon-Ferre RA, Jonas SF, Salgado R, et al. JAMA.
Zhou I, Plana D, Palmer AC. Clinical Cancer Research.
Lane MM, Gamage E, Du S, et al. BMJ.
Gelderblom H, Bhadri V, Stacchiotti S, et al. The Lancet.
Dhillon S. Molecular diagnosis & therapy.
The history entries editors wrote on cancer records: the dated turning points of each disease.
HR-positive / HER2-negative breast cancer
Limited-stage small-cell lung cancer
Sarcomas (soft tissue, bone, GIST)
Sarcomas (soft tissue, bone, GIST)
Synovial sarcoma
Resectable stage I to III non-small-cell lung cancer
ALK-positive non-small-cell lung cancer
Endometrial cancer
Craniopharyngioma. Vemurafenib plus cobimetinib produces responses in nearly all BRAF V600E papillary craniopharyngiomas (Lancet Oncology).
Bladder & urothelial cancer
Smouldering multiple myeloma
Rhabdomyosarcoma
Chronic myeloid leukaemia, chronic phase
Chronic myeloid leukaemia (CML). ASC4FIRST: higher MMR at 48 weeks than investigator-selected TKI; FDA accelerated approval October 2024.
Small intestine cancer (small bowel adenocarcinoma)
NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia
Mesothelioma
Standard-risk B-cell acute lymphoblastic leukaemia in children
High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
Adolescent and young adult cancers (ages 15 to 39)
Acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia. Immunotherapy becomes part of standard first-line therapy for adults and children; second CAR-T for adult ALL; revumenib approved for KMT2Ar leukaemi...
BRAF V600E-mutant colorectal cancer
Relapsed or refractory chronic lymphocytic leukaemia
Lung neuroendocrine tumours (typical and atypical carcinoid)
Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)
Mismatch-repair deficient (MSI-high) colorectal cancer
Ductal carcinoma in situ (DCIS). Hwang and colleagues (JAMA, December 2024); first randomised evidence for monitoring low-risk DCIS.
Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Advanced cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma
Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)
Cancer of unknown primary (CUP)
HER2-low and HER2-ultralow metastatic breast cancer
HER2-positive breast cancer with brain metastases
Brain metastases (secondary brain tumours)
Hepatocellular carcinoma
Follicular lymphoma
Oesophageal and junctional adenocarcinoma
KRAS G12C-mutant colorectal cancer
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Astrocytoma, IDH-mutant (grades 2 to 4)
Chronic lymphocytic leukaemia. Liso-cel accelerated approval (March); AMPLIFY fixed-duration acalabrutinib-venetoclax at ASH.
Pheochromocytoma and paraganglioma (PPGL). Baudin and colleagues, Lancet: first randomised trial in metastatic PPGL.
Metastatic pheochromocytoma and paraganglioma
Lung cancer (all types). ALINA gave adjuvant alectinib after resection of ALK-positive disease (93.8 against 63.0 percent disease-free at two years), LAURA gave osimertinib after c...
PD-L1-high non-small-cell lung cancer without a driver mutation
Hodgkin lymphoma
Primary mediastinal (thymic) large B-cell lymphoma
Myelodysplastic syndromes / neoplasms (MDS). IMerge: telomerase inhibitor achieves durable transfusion independence after ESA failure.
Lower-risk myelodysplastic syndromes
Newly diagnosed multiple myeloma, transplant-ineligible
HR-positive metastatic breast cancer after CDK4/6 inhibitors
Relapsed and refractory acute lymphoblastic leukaemia in children
Anal high-grade squamous intraepithelial lesions (precursor)
Vestibular schwannoma (acoustic neuroma). Plotkin and colleagues (NEJM) report the first platform trial in the condition.
Early triple-negative breast cancer
Renal cell carcinoma
Mismatch-repair-deficient endometrial cancer
KRAS G12C-mutant non-small-cell lung cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Non-small-cell lung cancer
Unresectable stage III non-small-cell lung cancer
Advanced melanoma (unresectable stage III and stage IV)
Melanoma
MET exon 14 and MET-amplified non-small-cell lung cancer
Triple-negative breast cancer (TNBC). Leon-Ferre and colleagues, 1,966 untreated patients: five-year distant recurrence-free survival 94 percent with lymphocytes of 50 percent or m...
EGFR-mutated non-small-cell lung cancer
Pleural mesothelioma
Mesothelioma
Tenosynovial giant cell tumour (TGCT). Gelderblom and colleagues, Lancet.
Melanoma
Stage III melanoma (after surgery)
Pancreatic ductal adenocarcinoma
Pancreatic neuroendocrine tumours
Grade 3 well-differentiated neuroendocrine tumour
Neuroendocrine tumours
Small intestinal neuroendocrine tumours
Neuroendocrine tumours
Muscle-invasive and advanced bladder cancer
Non-muscle-invasive bladder cancer
Resectable pancreatic ductal adenocarcinoma
Localised prostate cancer, very low and low risk
Localised prostate cancer, intermediate risk
Advanced or recurrent endometrial cancer
Cervical cancer
Locally advanced cervical cancer
Pleural mesothelioma
Multiple myeloma
Newly diagnosed multiple myeloma, transplant-eligible
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)
HER2-positive breast cancer
Early HER2-positive breast cancer
Anal cancer (squamous cell carcinoma). FDA approval 2025.
Diffuse midline glioma, H3 K27-altered (including DIPG). Durable objective responses in recurrent H3 K27M DMG reported in JCO; ACTION phase 3 open.
Borderline resectable pancreatic ductal adenocarcinoma
Appendiceal cancer and pseudomyxoma peritonei
NTRK fusion-positive non-small-cell lung cancer
Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)
Acute myeloid leukaemia in children
Acute myeloid leukaemia
Acute myeloid leukaemia. Approved for KMT2A-rearranged acute leukaemia (AUGMENT-101). Magrolimab (CD47) discontinued after ENHANCE trials, a setback for TP53-mutated AML.
Early cervical cancer and fertility-sparing surgery
Colorectal cancer
Prostate cancer
Diffuse large B-cell lymphoma
Undifferentiated pleomorphic sarcoma (UPS)
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
Extensive-stage small-cell lung cancer
Small-cell lung cancer
Extrapulmonary neuroendocrine carcinoma
Neuroendocrine and small-cell prostate cancer
Lung cancer (all types)
Cutaneous squamous cell carcinoma. Twelve kidney transplant recipients given cemiplimab after cross-taper to a mammalian target of rapamycin inhibitor with pulsed steroids: no reje...
Colorectal cancer. An Fc-enhanced CTLA-4 antibody with a PD-1 antibody gave 17% responses and 61% disease control in 101 evaluable heavily pre-treated microsatellite-stable patient...
Plasmablastic lymphoma. Across 1,153 SEER and 1,822 National Cancer Database patients, incidence was 0.07 per 100,000 a year, median overall survival among those given multi-agent...
Breast cancer (all types). RCPath G148 version 3 (November 2024) adds the ER low positive category, a separate section on male breast disease, updated handling of specimens after n...
Oesophageal cancer
Recurrent or metastatic cervical cancer
Paediatric low-grade glioma. FIREFLY-1 (Nature Medicine 2024) shows durable responses across fusions and V600E; FDA accelerated approval April 2024.
p53-abnormal endometrial cancer, including uterine serous carcinoma
Advanced and metastatic small bowel adenocarcinoma
Mantle cell lymphoma. Ibrutinib replaces transplant in fit patients; acalabrutinib + BR improves PFS first line in older patients.
Head and neck squamous cell carcinoma
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
HER2-amplified colorectal cancer
Mucosal melanoma
Acral melanoma
Triple-negative breast cancer (TNBC). ASCO-SSO recommends BRCA1/2 testing for all breast cancer diagnosed at 65 or under and for every PARP inhibitor candidate.
Higher-risk myelodysplastic syndromes
Glioma & glioblastoma
Brain and spinal cord tumours (all types). First targeted drug for grade 2 astrocytoma and oligodendroglioma after surgery (INDIGO trial).
Gallbladder cancer. FDA accelerated approval (November 2024) on HERIZON-BTC-01, in which gallbladder cancer was the largest subgroup.
Biliary tract cancer (cholangiocarcinoma)
Extrahepatic cholangiocarcinoma (perihilar and distal)
Biliary tract cancer (cholangiocarcinoma)
Metastatic pancreatic ductal adenocarcinoma
KRAS wild-type pancreatic ductal adenocarcinoma
Gastric & gastro-oesophageal junction cancer
Oesophageal and junctional adenocarcinoma
Claudin 18.2-positive gastric cancer
Gastric & gastro-oesophageal junction cancer
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The funding rounds on company records, each with the source that states the figure.
$135m
$18m. Equity offering, first sale 31 July 2024
$181m
$175m
$100m. 6.25 million shares at 16 US dollars; closed 2 April 2024
$70m. $70 million in Veracyte shares at closing plus up to $25 million in milestone payments over two years; definitive agreement announced 8 January 2024.
$87m. Amount sold at filing of a $175 million offering, first sale 5 March 2024
$22m. Health Catalyst acquired Carevive Systems on 24 May 2024 for USD 18.6 million net cash, USD 2.6 million in shares and USD 0.9 million contingent earn out; announced 6 June 20...
$6m. Late filing made 20 November 2024 for an equity offering first sold 29 November 2017; includes USD 3.4 million of converted notes
$17m. Late filing made 20 November 2024 for an equity offering first sold 17 September 2019; includes USD 6.1 million of converted notes
$27m. Late filing made 20 November 2024 for an equity offering first sold 26 April 2022; USD 26.9 million sold of USD 33.8 million
$100m. Led by the Life Sciences group of J.P. Morgan Private Capital
$94m
$24m. Total sold of a 36 million US dollar offering per Form D filed May 2024
$126m. Total sold per Form D filed August 2024
$680m. $23.00 per share in cash, approximate total equity value $680 million; announced 8 January 2024, completed 11 March 2024
$2.2bn. Predecessor Inhibrx, Inc. sold its INBRX-101 (alpha-1 antitrypsin) asset to Sanofi for about 2.2 billion US dollars aggregate value; oncology assets were spun out into Inhi...
Acquired by DeepHealth, a wholly owned subsidiary of RadNet, announced 22 October 2024; terms not disclosed.
$1.0bn. USD 1 billion upfront plus up to USD 750 million in milestones
$40m
$2m. National Cancer Institute SBIR grant, per company website
$120m
$1.8bn. All-cash deal announced 3 April 2024; Nasdaq copy of the Genmab company announcement
$53m. Brought total raised to USD 82.5 million
$126m. Total sold of a 150 million US dollar offering per Form D filed July 2024
$46m. ARPA-H award of up to USD 46 million (Dec 2024) for sonodynamic therapy in haematologic malignancies; milestone-contingent
$422m. Total sold per Form D filed October 2024
Series B closed August 2024 with existing investors including Quest Diagnostics and new investors including Olympus Innovation Ventures; extension amount not disclosed.
$22m. Co-led by DCVC and a16z with existing investor Pear VC, May 2024.
Lunit's November 2025 release states the acquisition of Volpara Health Technologies was completed in 2024; value not stated in the fetched source.
$78m. Led by Qingdao Baheal Medical with participation from other strategic investors
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Lancet
Lancet Oncology
Lancet
European Heart Journal
Cancer Discovery
Annals of Oncology
The Lancet Oncology
Lancet
New England Journal of Medicine
NEJM
Vaccines
Cancers
Lancet
New England Journal of Medicine
NEJM
New England Journal of Medicine
Nature Communications
The Lancet Oncology
The Lancet Oncology
Lancet Oncology
Cancer Immunology, Immunotherapy
Healthcare
NEJM
BMJ Oncology
Lancet Oncol
Heliyon
Clinical and Translational Radiation Oncology
Journal of Clinical Oncology
NEJM
New England Journal of Medicine
Annals of Oncology
Breast Cancer Research
European Journal of Surgical Oncology
Lancet Respiratory Medicine
Annals of Oncology
Neuro-Oncology Advances
Nature Communications
npj Precision Oncology
CA: A Cancer Journal for Clinicians
Lancet
Lancet Haematology
Lancet
NEJM
NEJM
Transplant International
The Lancet Haematology
Lancet
Lancet
Science Immunology
NEJM
JAMA
JAMA
The Lancet
Journal of Clinical Oncology
Journal of Clinical Oncology
International Journal of Molecular Sciences
Nature Communications
Journal of Thoracic Oncology
Lancet
NEJM
NEJM
Nature Medicine
Lung Cancer
New England Journal of Medicine
NEJM
New England Journal of Medicine
Blood
Journal for ImmunoTherapy of Cancer
JCO
Acta Oncologica
Lancet
NEJM
NEJM
Journal for ImmunoTherapy of Cancer
Ann Oncol
Lancet Haematology
New England Journal of Medicine
Lancet Oncology
Breathe (Sheff)
American Society of Clinical Oncology Educational Book
Lancet Oncology
Cancers
Cancer Research Communications
Clinical Cancer Research
JAMA Pediatrics
Lancet
Nature
NEJM
Nature Medicine
Journal of Gastrointestinal Surgery
Nature Medicine
Dates a source states for something still to come: roadmap watch items, the readout calendar, company catalysts, and registry primary completion dates.
Actual primary completion date on ClinicalTrials.gov.
Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.
Actual primary completion date on ClinicalTrials.gov.